Frontlight ResearchEarly access
CompletedNo phase
Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism
Key facts
- Who runs it
- Angiodynamics, Inc.
- Where
- Atlanta, Buffalo, Columbus, Dallas, Erie, Houston, Indianapolis, Jacksonville, Jefferson, Knoxville, Los Angeles, Miamisburg, Milwaukee, Montgomery, Munster, New Haven, New York, Newark, Peoria, Pittsburgh, Saint Cloud, San Antonio, Scottsdale, and The Bronx, United StatesSee the 25 sites
- Trial code
- Status
- Completed
- People taking part
- 122 people enrolled
- Started
- 19 Oct 2022
- Ended
- 4 Jan 2024
- Type of study
- Interventional
- Treatments tested
- AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE
- Record updated
- 19 July 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Signed and dated informed consent form
- 18 years of age and older
- Clinical signs and symptoms consistent with acute intermediate-risk pulmonary embolism for less than or equal to 14 days
- Diagnosis of pulmonary embolism detected from computed tomography angiography (CTA)
- Right Ventricle to Left Ventricle (RV/LV) ratio of 0.9 or higher
- Systolic blood pressure (SBP) of 90 mmHg or higher
- Heart rate of 130 beats per minute (BPM) or less prior to the procedure
- Deemed medically eligible for interventional procedure(s) per institutional guidelines and/or clinical judgment
Who cannot take part
- Has had a cardiovascular or pulmonary surgery within the past 7 days of index procedure
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- Has pulmonary hypertension with peak pulmonary artery pressure (PAP) > 70 mmHg
- Presence of cancer requiring active chemotherapy
- Known bleeding diathesis or coagulation disorder
- Platelets count < 100,000/µL
- Serum creatinine >1.8 mg/dL
- International Normalized Ratio (INR) > 3
- History of severe or chronic pulmonary hypertension, uncompensated heart failure, chest irradiation, underlying lung disease that is oxygen dependent, Heparin-induced thrombocytopenia (HIT) and/or chronic left heart disease with left ventricular ejection fraction ≤ 30%
- Excluded from the study if he/she meets any of the following exclusion criteria
- May be pregnant as determined by a positive pregnancy test or who are breastfeeding
- Has any contraindication to systemic or therapeutic doses of heparin or anticoagulants
- Has used thrombolytics (tPA) in the past 30 days of baseline CTA
- Fraction of inspired oxygen (FiO2) requirement >40% or >6 liters per minute (LPM) to keep oxygen saturations >90%
- Hematocrit <28% within 6 hours of the index procedure
- Has undergone a major trauma within the past 14 days of the index procedure and have Injury Severity Score (ISS) > 15
- Requires Vasopressor after fluids to keep pressure ≥ 90 mmHg
- With left bundle branch block
- Has intracardiac lead in the right ventricle or atrium
- Evidence such as imaging or other that suggests the subject is not appropriate for this procedure
- Has life expectancy < 90 days
- Dependent on extracorporeal life support such as extracorporeal membrane oxygenation (ECMO)
- Participation in another investigational study
Where in United States
- Emory University at Grady Memorial HospitalAtlanta, United States
- Piedmont Heart InstituteAtlanta, United States
- University of BuffaloBuffalo, United States
- Ohio State University Wexner Medical CenterColumbus, United States
- Baylor Heart and Vascular HospitalDallas, United States
- UPMC HamotErie, United States
- Memorial Hermann (University of Texas at Houston)Houston, United States
- Indiana UniversityIndianapolis, United States
- HCA Memorial Hospital JacksonvilleJacksonville, United States
- Oshner Medical CenterJefferson, United States
- Tennova Healthcare-Turkey Creek Medical CenterKnoxville, United States
- UCLA HealthLos Angeles, United States
- Kettering HealthMiamisburg, United States
- Aurora Health CareMilwaukee, United States
- Einstein Medical CenterMontgomery, United States
- Community HospitalMunster, United States
- Yale UniversityNew Haven, United States
- Columbia University Medical Center/NYPHNew York, United States
- Rutgers UniversityNewark, United States
- OSF HealthCarePeoria, United States
- UPMC PittsburghPittsburgh, United States
- Centracare Heart and Vascular CenterSaint Cloud, United States
- Methodist HospitalSan Antonio, United States
- HonorHealthScottsdale, United States
- Jacobi Medical CenterThe Bronx, United States
About the trial
What the trial wants to find out
To evaluate the safety and effectiveness of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE in a prospective trial of patients with acute intermediate-risk pulmonary embolism (PE).
The group in the trial
- AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PETreatment being tested
Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for the treatment of acute pulmonary embolism
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 19 July 2024